Drug intelligence / Profile preview

VRB-101 + VRB-102

Development stage: Preclinical
Lead developer: Verdiva Bio
Modality: Peptides
Administration: Subcutaneous

Overview

VRB-101 + VRB-102 is an injectable peptide combination therapy being developed by Verdiva Bio for the treatment of obesity. The formulation consists of VRB-101, a cAMP-biased glucagon-like peptide-1 (GLP-1) receptor agonist (ecnoglutide), and VRB-102, an amylin receptor analog. This co-formulation is designed for once-weekly subcutaneous administration to leverage the synergistic effects of GLP-1 and amylin signaling on appetite regulation and metabolic control. By combining these two mechanisms, the drug aims to provide superior weight loss efficacy compared to monotherapy. It is currently in the IND-enabling stage of development.

Other names: VRB-102 + ecnoglutide

Targets

AMY receptor (Calcitonin receptor (with ramps))GLP1R (GLP-1R)

Beyond the preview

Go deeper on VRB-101 + VRB-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRB-101 + VRB-102.

Explore the full profile